Idexx Laboratories (IDXX) Asset Writedowns and Impairment (2009 - 2026)

Idexx Laboratories (IDXX) posted Asset Writedowns and Impairment of $5.0 million for Q1 2026, up 1900.0% on a QoQ basis from $250000.0 in Q1 2024.

Analysis

Idexx Laboratories (IDXX) Asset Writedowns and Impairment (2009 - 2026) Analysis & Trends

Idexx Laboratories has reported Asset Writedowns and Impairment for 15 years, with the latest figure at $5.0 million in Q1 2026.

On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $5.0 million in Q1 2026; TTM through Jun 2026 was $5.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $250000.0, down 83.15% from the prior year.
Asset Writedowns and Impairment was $5.0 million for Q1 2026 at Idexx Laboratories, up from $250000.0 in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $5.0 million in Q1 2026, with the low at $250000.0 in Q1 2024.
Average Asset Writedowns and Impairment over 3 years is $2.2 million, with a median of $1.5 million recorded in 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Idexx Laboratories	40.57 Bn	40.38 Bn	779.09 Mn
2	Zoetis	30.57 Bn	28.90 Bn	1.05 Bn
3	Elanco Animal Health	11.47 Bn	10.94 Bn	798.00 Mn
4	Phibro Animal Health	1.43 Bn	1.35 Bn	134.40 Mn
5	Immucell	87.38 Mn	78.52 Mn	2.44 Mn
6	Zhengye Biotechnology Holding	64.40 Mn	57.30 Mn	-
7	Global Innovative Platforms	24.88 Mn	24.63 Mn	-

Historic Data

Download Data